Acrux(OTC) ARUXF

Market Cap$8.85M

Since IPO (2008)-98%

5 Year-80%

1 Year-58%

1 Month+1%

$0.02

+0%

+0.00Today

Acrux last closing stock price
Metric	Price	Date
Last close	USD 0.02	2026-06-22

Acrux stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.02	2026-06-03
1 month	+0.93%	USD 0.02	2026-05-19
3 month	+275.56%	USD 0.00	2026-01-08
Year to date	+4%	USD 0.02	2025-12-31
1 year	-57.75%	USD 0.04	2025-04-30
3 year	-60.97%	USD 0.04	2023-06-14
5 year	-80.28%	USD 0.09	2021-06-15
Since inception	-98.28%	USD 0.98	2008-01-25

Acrux Financials at a Glance

Market Cap

$8.85M

Revenue (TTM)

A$3.61M

Net Income (TTM)

-A$8.34M

EPS (TTM)

-$0.00

P/E Ratio

-4.57

Dividend

$0.00

Beta (Volatility)

-0.67 (Low)

Dividend

$0.00

Beta (Volatility)

-0.67 (Low)

Price

$0.02

Volume

Open

$0.02

Price

$0.02

Volume

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.00 - $0.05

Estimated Earnings Date

Aug 21, 2026

Dividend

$0.00

Beta (Volatility)

-0.67 (Low)

Price

$0.02

Volume

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.00 - $0.05

Estimated Earnings Date

Aug 21, 2026

ARUXF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Acrux

Acrux Limited specializes in the global development and commercialization of generic and topical pharmaceutical products. The company focuses on testosterone therapies and estradiol sprays, catering to both men and women with specific health needs.

Products and Services

Diverse testosterone therapies in various forms
Estradiol sprays for menopausal women
Topical pharmaceutical products for global markets

Growth Outlook

Recent quarterly revenue reached AUD 1,739,316, showing potential for growth
Strong gross profit margin of 87.24% in the latest quarter
Expansion into international markets enhances growth opportunities

Financial Highlights

Trailing twelve months revenue of AUD 4,409,000
Net income of AUD 164,934 in the latest quarter
Current ratio of 1.35 indicates solid short-term financial health

Acrux Limited operates in the biotechnology sector, focusing on innovative solutions for hormone-related health issues. The company has established a strong presence in international markets, including Australia, Europe, and the United States. Recent financial performance indicates a positive trajectory, with a notable increase in quarterly revenue and a strong gross profit margin. The company's diverse product offerings and commitment to addressing specific health needs position it well for future growth. With a solid current ratio, Acrux Limited demonstrates its ability to manage short-term obligations effectively. Overall, the company presents an intriguing opportunity for investors interested in the biotechnology sector.

AI Generated • Jul 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

John Warmbrunn

Website

www.acrux.com.au

Headquarters

West Melbourne, VIC 3003, AU

ARUXF Financials

Key Financial Metrics (TTM)

Gross Margin

56.94%

Operating Margin

-185.41%

Net Income Margin

-83.81%

Return on Equity

-211.88%

Return on Capital

-192.61%

Return on Assets

-49.76%

Earnings Yield

-21.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.85M

Shares Outstanding

523.91M

Volume

Avg. Volume

1.79K

Financials (TTM)

Gross Profit

-A$1.81M

Operating Income

-A$15.19M

EBITDA

-A$13.67M

Operating Cash Flow

-A$6.83M

Capital Expenditure

-A$125.00K

Free Cash Flow

-A$6.95M

Cash & ST Invst.

A$945.63K

Total Debt

A$3.64M

Acrux Performance Analysis

Acrux annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-06-30	AUD 1,246,766	N/A
2023	2023-06-30	AUD 5,670,226	354.8%
2024	2024-06-30	AUD 3,336,514	-41.2%
2025	2025-06-30	AUD 770,681	-76.9%

Acrux sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-06-30	-84.5%
Q2	2024-12-31	-82.4%
Q4	2025-06-30	791.7%
Q2	2025-12-31	62.6%

Acrux annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-06-30	AUD -0.03	N/A
2023	2023-06-30	AUD -0.00	-92.8%
2024	2024-06-30	AUD -0.01	627.8%
2025	2025-06-30	AUD -0.01	-16.8%

Acrux sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-06-30	21.4%
Q2	2024-12-31	-29.5%
Q4	2025-06-30	44.7%
Q2	2025-12-31	106.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

A$1.74M

-60.6%

Gross Profit

A$1.52M

+166.7%

Gross Margin

87.24%

N/A

Market Cap

$8.85M

N/A

Market Cap/Employee

$205.91K

N/A

Employees

N/A

Net Income

A$164.93K

+105.1%

EBITDA

-A$1.07M

+73.1%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

A$945.63K

-79.3%

Total Debt

A$3.64M

+61.1%

Accounts Receivable

A$1.63M

-58.6%

Inventory

A$0.00

N/A

Long Term Debt

A$2.88M

-12.2%

Short Term Debt

A$755.70K

+23.9%

Return on Assets

-49.76%

N/A

Return on Invested Capital

-1.94%

N/A

Free Cash Flow

A$1.53M

+197.2%

Operating Cash Flow

A$1.53M

+207.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IBOGFUniversal Ibogaine Inc.

IBOGFUniversal Ibogaine Inc.$0.03+9.81%

ZLDAFZelira Therapeutics Limited

ZLDAFZelira Therapeutics Limited$0.30+0.00%

AGNPFGrey Matters Health Inc.

AGNPFGrey Matters Health Inc.$0.30+0.00%

AXIMAXIM Biotechnologies, Inc.

AXIMAXIM Biotechnologies, Inc.$0.00+0.00%

SIGYSigyn Therapeutics, Inc.

SIGYSigyn Therapeutics, Inc.$0.03+0.00%

PKTXProtoKinetix, Incorporated

PKTXProtoKinetix, Incorporated$0.00+0.00%

REPCFRepliCel Life Sciences Inc.

REPCFRepliCel Life Sciences Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$19.63-0.20%

NOKNokia

NOKNokia$8.41-0.06%

SKHYSK Hynix

SKHYSK Hynix$126.79-0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$57.75-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$6.74-0.06%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$49.44+0.06%

INTCIntel

INTCIntel$81.88-0.05%

Questions About ARUXF

What is the current price of Acrux?

Acrux is trading at $0.02 per share.

What is the 52-week range for Acrux?

Over the past 52 weeks, Acrux has traded between $0.00 and $0.05.

How much debt does Acrux have?

As of the most recent reporting period, Acrux reported total debt of A$2.38M.

How much cash does Acrux have on hand?

Acrux reported A$565.57K in cash and cash equivalents in its most recent financial results.

What is Acrux’s dividend yield?

Acrux does not currently have a dividend yield.

Acrux(OTC) ARUXF

Acrux Financials at a Glance

ARUXF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Acrux

ARUXF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Acrux Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ARUXF

What is the current price of Acrux?

What is the 52-week range for Acrux?

How much debt does Acrux have?

How much cash does Acrux have on hand?

What is Acrux’s dividend yield?

Premium Investing Services